Effect of erythropoietin stimulating agent on endothelial function in non-dialysis chronic kidney disease patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003914

Enrollment

Registered

2019-05-14

Start date

2017-06-01

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Erythropoietin agent (mircera) dose 50 mcg, 100 mcg, 200 mg, frequency: once a month, period: within the study period, injection path: hypodermic injection No differences between arbitrators as

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a person who has signed a written consent form of 10,000 to 20 years of age or older. Patients with chronic kidney disease stage 4,5 (GFR 10-30 ml/min/1.73 m2) without dialysis Blood colouring (Hb) 55%)

Exclusion criteria

Exclusion criteria: a history of erythropoietin administration within the last three months. A person who is subject to or needs to perform dialysis. Uncontrolled hypertension an expected life expectancy of less than one year Someone who needs surgery for meaningful valve disease Any person who has evidence of acute coronary syndrome within 60 days; Patients with heart failure due to acute myocarditis, limited myocardial infarction and deadlocked myocardial infarction Anemia with severe bleeding (Hb 3 mg/dL, albumin < 2.8 mg/dL) Pregnant women, nursing mothers Persons currently participating in other clinical trials

Design outcomes

Primary

Measure	Time frame
function of endothelial cell	—

Secondary

Measure	Time frame
New York Heart Association class	—

Countries

Korea, Republic of

Contacts

Public ContactHoon Yu

University of Ulsan

hoon2345@naver.com+82-33-610-3131

Outcome results